Keywords: alexion, eculizumab, bolstered, study, new, conducted, usa

Alexion's eculizumab bolstered by study

Article | 30 May 2005

A new study conducted by the USA's Alexion Pharmaceuticals suggests that treatment with an anti-C5 complement blocking antibody significantly reduces ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

eculizumab

Soliris

Go to drug listing